Precigen Inc PGEN:NASDAQ

Last Price$1.38Cboe Real-Time Last Sale as of 11:00AM ET 6/27/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.02(1.43%)
Bid (Size)$1.37 (105)
Ask (Size)$1.38 (1,900)
Day Low / High$1.33 - 1.40
Volume119.5 K
 

View Biotechnology IndustryPeer Comparison as of 06/27/2022

 

Precigen Inc ( NASDAQ )

Price: $1.38
Change: -0.02 (1.43%)
Volume: 119.5 K
11:00AM ET 6/27/2022
 
 

Scholar Rock Holding Corp ( NASDAQ )

Price: $7.03
Change: +1.07 (17.95%)
Volume: 506.3 K
11:00AM ET 6/27/2022
 
 

Seres Therapeutics Inc ( NASDAQ )

Price: $3.37
Change: -0.01 (0.44%)
Volume: 100.0 K
11:00AM ET 6/27/2022
 
 

bluebird bio Inc ( NASDAQ )

Price: $4.20
Change: -0.20 (4.55%)
Volume: 1.7 M
11:02AM ET 6/27/2022
 
 

Alpine Immune Sciences Inc ( NASDAQ )

Price: $8.70
Change: 0.00 (0.00%)
Volume: 10.1 K
10:58AM ET 6/27/2022
 

Read more news Recent News

-- Earnings Flash (PGEN) PRECIGEN Reports Q1 Revenue $32M, vs. Street Est of $23.3M
4:39PM ET 5/09/2022 MT Newswires

...

Precigen's Acute Myeloid Leukemia Treatment Candidate Gets FDA Fast Track Designation
11:04AM ET 4/04/2022 MT Newswires

Precigen (PGEN) said Monday the US Food and Drug Administration granted fast track designation to its PRGN-3006 UltraCAR-T treatment for relapsed or...

-- Earnings Flash (PGEN) PRECIGEN Reports Q4 Revenue $24.2M, vs. Street Est of $22.2M
8:02AM ET 3/01/2022 MT Newswires

...

Insider Buy: Precigen
5:06PM ET 11/30/2021 MT Newswires

Harry Thomasian Jr., Chief Financial Officer, on November 26, 2021, executed a purchase for 26,500 shares in Precigen (PGEN) for $100,831. Following the...

Company Profile

Business DescriptionPrecigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD. View company web site for more details
Address20358 Seneca Meadows Parkway
Germantown, Maryland 20876
Phone+1.301.556.9900
Number of Employees882
Recent SEC Filing06/14/20228-K
President, Chief Executive Officer & DirectorHelen Sabzevari
Vice President, Head-Operations & PortfolioRutul R. Shah
Chief Financial OfficerHarry Thomasian
Chief Science OfficerThomas David Reed

Company Highlights

Price Open$1.39
Previous Close$1.40
52 Week Range$1.12 - 6.96
Market Capitalization$286.6 M
Shares Outstanding207.7 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement08/08/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.47
Beta vs. S&P 500N/A
Revenue$160.6 M
Net Profit Margin-84.55%
Return on Equity-79.87%

Analyst Ratings as of 05/10/2022

Buy
4
Overweight
0
Hold
1
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset